Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dovitinib in Stage IV HER2-negative Inflammatory Breast Cancer
NCT01262027Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2012
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dovitinib in inflammatory breast cancer (IBC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Overall Response (Complete Response [CR], Partial Response [PR] or Stable Disease [SD]) at 6 months. Started Jan 2012; status: completed.
02
Drugs
dovitinib
03
Conditions
inflammatory breast cancer (IBC)
Beyond the preview
Go deeper on NCT01262027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01262027.